Health News Releases

March 30, 09:30

Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global an

March 29, 11:45

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care

Takeda (TSE:4502/NYSE:TAK) today announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adult

March 29, 11:25

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis

Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clin

March 29, 10:25

Biocytogen Announces FDA IND Clearance for Partner NEOK Bio’s NEOK002 Targeting Solid Tumors

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innova

March 27, 12:00

Rubedo Life Sciences Announces Positive Preliminary Phase 1 Clinical Trial Results for Lead Drug Candidate RLS-1496 in Patients with Plaque Psoriasis, Atopic Dermatitis, and Skin Aging

Rubedo Life Sciences, Inc. (https://www.rubedolife.com/) (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targetin

March 27, 11:10

Invivoscribe® Expands IVDR Portfolio with IdentiClone® Dx IGH Assay Certification

Invivoscribe, a global leader in precision diagnostics and measurable residual disease (MRD) testing, is proud to announce that its IdentiClone Dx IGH Assay has received In Vitro Diagnostic Regulation

March 26, 16:30

Apimeds Pharmaceuticals US Inc. Announces Material Breach of Merger Agreement by Inscobee Inc. (KS:006490) and Apimeds Inc.; Prepares Filing Emergency Action in Delaware Court of Chancery

MindWave Innovations Inc., a Delaware corporation and wholly owned subsidiary of Apimeds Pharmaceuticals US, Inc. (“APUS” or the “Company”) (NYSE American: APUS), today announced that on March 20, 202

March 25, 15:50

Hyperice Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026

Hyperice (https://hyperice.com/), a high-performance wellness brand, has been named to Fast Company’s (https://www.fastcompany.com/) prestigious list of the World’s Most Innovative Companies of 2026.

March 24, 16:39

AAD 2026: Galderma Showcases Latest Evidence Supporting Its Full-Spectrum, Science-Driven Solutions for Diverse Skin Needs

Galderma (SIX: GALD), the pure-play dermatology category leader, will present the latest updates on its innovations across its broad portfolio at the 2026 American Academy of Dermatology (AAD) Annual

March 24, 15:20

Biocytogen Announces Strategic Collaboration with Moonlight Bio to Advance Cell Therapies Using Library of Antibody Binders

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innova

March 23, 15:50

Galderma Receives U.S. FDA Approval for Restylane® Contour™ for the Correction of Temple Hollowing

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the U.S. FDA has approved Restylane Contour for the correction of temple hollowing in patients over the age of 21.

March 20, 15:52

Galderma Publishes Invitation and Agenda for Its 2026 Annual General Meeting

Galderma Group AG (SIX: GALD), the pure-play dermatology category leader, today published the invitation and agenda for its 2026 Annual General Meeting (AGM), which will be held virtually on April 22,

March 18, 16:38

Samsung Bioepis Enters into Partnership Agreement with Sandoz for Up to Five Next-Generation Biosimilar Candidates

Samsung Bioepis Co., Ltd. announced today that the company has entered into a global license, development and commercialization agreement (DCA) with Sandoz for up to five biosimilar candidates under d

March 18, 15:55

DNA Script Expands Global Access to On-demand DNA Synthesis With Distributor Agreements in Latin America and East Asia

DNA Script, a pioneer in DNA synthesis providing scientists with rapid, on-demand access to high-quality DNA, today announced it has signed distribution agreements with Gencell (https://cts.businesswi

March 17, 16:20

Fujirebio Announces CE Marking of the Fully Automated Lumipulse® G Nfl Blood Assay

H.U. Group Holdings Inc., and its wholly owned subsidiary, Fujirebio Holdings, Inc. (hereinafter “Fujirebio”) today announced that Fujirebio Europe N.V. has obtained a CE Certificate of the Lumipulse

March 17, 16:00

AMWC 2026: Galderma Showcases Category‑leading Innovation With a Comprehensive Portfolio and Holistic, Future‑focused Aesthetic Strategies

Galderma (SIX: GALD) will present nine abstracts at the Aesthetic & Anti‑Aging Medicine (AMWC) World Congress 2026 in Monaco, showcasing innovative and robust scientific data across its aesthetics por

March 17, 11:30

SBC Medical Announces Opening of Brand Flagship “NEO Skin Clinic Ginza.”

SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Management Services Organization operating a wide range of franchise businesses across diverse medical fields,

March 16, 09:23

Samsung Bioepis and Epis NexLab Sign Research Collaboration and License Agreement with G2GBIO to Develop Novel Assets Including Long-acting Semaglutide

Samsung Bioepis Co., Ltd. and Epis NexLab Co., Ltd., a sister company to Samsung Bioepis under Samsung Epis Holdings (KRX: 0126Z0), today announced a research collaboration and license agreement with

March 15, 13:30

WHOOP and Samuel Ross MBE Announce First Limited-Edition Collection Drop for PROJECT TERRAIN

WHOOP (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.whoop.com%3Futm_source%3DPR%26utm_medium%3DPR%26utm_campaign%3DSR_A&esheet=54443959&newsitemid=20260312513358&lan=en-US&anc

March 13, 15:55

C2N Diagnostics Enters South Korean Market Through Partnership with BeauBrain Healthcare to Offer Precivity™ Portfolio of Blood Tests to Help Doctors Diagnose Alzheimer’s Disease

C2N Diagnostics, LLC (https://c2n.com/) (“C2N”), a specialty diagnostics company with a vision to bring Clarity Through Innovation®, has reached an agreement with BeauBrain Healthcare (https://beaubra

March 13, 11:40

Andersen Consulting Strengthens Platform with Collaborating Firm Ambit Iberia

Andersen Consulting expands its technology and business transformation capabilities through a Collaboration Agreement with Ambit Iberia, a consulting firm specializing in digital and regulatory soluti

March 12, 16:10

Veristat Expands Regulatory and Clinical Services to Chinese Drug and Device Companies Seeking Efficient Way to Enter European Markets

Veristat (https://www.veristat.com/), a global clinical research organization (CRO) and consultancy specializing in complex studies, announced expanded regulatory and clinical trial services to intern

March 12, 15:55

InterSystems Appoints Former NHS and Mass General Leader Dr. Tim Ferris as Vice President, Healthcare Practice

InterSystems, a creative data technology provider powering more than one billion health records globally, today announced the appointment of Tim Ferris, M.D., as Vice President, Healthcare Practice. T

March 12, 15:10

Hyperice Introduces Hypervolt 3 Line: More Powerful, Quieter, and Longer-Lasting Percussion Massage Devices

Hyperice (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fhyperice.com%2F&esheet=54442271&newsitemid=20260310934508&lan=en-US&anchor=Hyperice&index=1&md5=9dae1327c39b94f4b0ce095f7d63

March 12, 08:36

Chiesi and Bespak Partner to Advance Carbon Minimal Inhaler Production With UK Manufacturing Site

Chiesi Group (“Chiesi”), the international research focused biopharmaceutical company and a certified B Corp, and Bespak, the specialist inhalation CDMO focused on pulmonary and nasal drug delivery, t

News by Region

News by Industry